Skip to main content

The Notorious Stephen Glass

Image result for Stephen Glass

An exchange of letters in the January 2016 issue of Harper's reminds me that back in the 1990s, when Stephen Glass was notoriously making stuff up for The New Republic, he also made stuff up in other publications as well.

An article of his ran in the Harper's for February 1998, titled "Prophets and Losses." It concerned telephone psychics, portraying a business in which phony psychics try to keep callers on the line as long as possible in order to sock them with astronomical charges. As was often the case with Glass' frauds, it is easy to believe the broad outlines of what he was saying, which is precisely why people weren't necessarily vigilant about the details, which he invented.

In the latest issue, Glass provides a paragraph by paragraph breakdown of what he fabricated for that story, a breakdown that will be unreadable for anyone who doesn't have the actual text of the story n front of them. Fortunately, this is 2016, and you can find that here.

The following is his paragraph five:

I've spent nearly every night of the last few months watching psychic infomercials. Like a lot of the characters in the ads, I'm concerned with my financial future, but unlike them I decide it would be more lucrative to become a psychic than consult with one. I track down the phone numbers of eight networks' corporate offices from ads on TV and the back pages of The Cable Guide. The man who answers the phone at LaToya Jackson's Psychic Network greets me with, "Yeah, and what the fuck do you want?" Before I can finish, he hangs up. At the Kenny Kingston Psychic Hotline a gum-chomping secretary spits, "No, we're not hiring. You should have known that since you're, like, the psychic." Three networks take my name: Psychic Friends Network (PFN), Psychic Encounters, and Psychic Believers Network (PBN).

He now acknowledges having fabricated the passage from "the man" to "the psychic." That is, the stuff I italicized above.  So apparently he did track down corporate numbers and did get three networks to take his name, but he had to enliven that information with a couple of made-up rejections.

Anyway, the editors reply, telling us that Glass has voluntarily returned the $10,000 they paid him for that piece. (When? recently? after keeping it interest free for almost 20 years?).


Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…